Table 3.
Known mutations present in the 60 samples that were analyzed in the blind during phase 2 of the panel validation
| Mutation | Unique samples | Identified |
|---|---|---|
| BRAF: p.Val600Glu | 3 | Yes |
| CTNNB1: p.Thr41Ile | 1 | Yes |
| CTNNB1: p.Asp32Asn | 1 | Yes |
| EGFR: p.Glu746_Arg748del | 1 | Yes |
| EGFR: p.Glu746_Ala750del | 4 | Yes |
| EGFR: p.Glu746_Ser752del | 1 | Yes |
| EGFR: p.Leu858Arg | 5 | Yes |
| KRAS: p.Gln61Arg | 1 | Yes |
| KRAS: p.Gly12Arg | 2 | Yes |
| KRAS: p.Gly12Cys | 5 | Yes |
| KRAS: p.Gly12Asp | 8 | Yes |
| KRAS: p.Gly12Ala | 2 | Yes |
| KRAS: p.Gly12Val | 7 | Yes |
| KRAS: P.Gly13Cys | 1 | Yes |
| KRAS: p.Gly13Asp | 5 | Yes |